NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $15.88 -0.26 (-1.61%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$16.15 +0.27 (+1.70%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nurix Therapeutics Stock (NASDAQ:NRIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$15.75▼$16.7650-Day Range$14.84▼$27.2652-Week Range$12.01▼$28.23Volume3.05 million shsAverage Volume4.29 million shsMarket Capitalization$1.73 billionP/E Ratio6.87Dividend YieldN/APrice Target$34.43Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down. Nurix’s pipeline includes investigational drug candidates, including BTK degraders being studied for B-cell cancers and candidates designed to affect immune-cell signaling. The company has also pursued research and development collaborations with pharmaceutical partners. Its medicines remain under investigation and are not established treatments.AI Generated. May Contain Errors. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreNRIX MarketRank™: 3.862587366475 of 5 starsNurix Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 199th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on no strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNurix Therapeutics has a consensus price target of $34.43, representing about 116.8% upside from its current price of $15.88.Amount of Analyst CoverageNurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from $1.14 to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is 6.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is 6.87, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.30.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.58% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 7.17.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 8.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.40 News SentimentNurix Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Nurix Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $893,645.00 in company stock.Percentage Held by Insiders6.70% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by InstitutionsNurix Therapeutics has minimal institutional ownership at this time.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRIX Stock News HeadlinesNurix Therapeutics to Participate in Upcoming Investor ConferencesNovember 10 at 7:00 AM | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Stock Breaks Below Two Hundred Day Moving Average Following Insider SellingNovember 6, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ...November 5, 2026 | markets.businessinsider.comNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ExpositionNovember 5, 2026 | globenewswire.comInsider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 4,769 Shares of StockNovember 5, 2026 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Company StockNovember 3, 2026 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Stock: Insider Julia Gregory Sells 22,583 SharesOctober 15, 2026 | insidertrades.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.97 at the start of the year. Since then, NRIX shares have decreased by 16.3% and is now trading at $15.88. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Tuesday, October, 13th. The company reported $4.73 EPS for the quarter, topping the consensus estimate of ($0.60) by $5.33. The company had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a trailing twelve-month return on equity of 49.34% and a net margin of 42.01%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $187 million in an initial public offering on Friday, July 24th 2020. The company issued 11,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional shareholders of Nurix Therapeutics include Pictet Asset Management Holding SA (1.03%), Sumitomo Mitsui Trust Group Inc. (0.79%), Russell Investments Group Ltd. (0.46%) and Candriam S.C.A. (0.34%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Julia P Gregory. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Marvell Technology (MRVL), Palantir Technologies (PLTR), Tesla (TSLA) and Vertex Pharmaceuticals (VRTX). Company Calendar Last Earnings10/13/2026Today11/11/2026UBS Global Biopharma Conference 202611/17/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End11/30/2026Next Earnings (Estimated)1/27/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, NRIX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees357Year Founded2012Price Target and Rating Average Price Target for Nurix Therapeutics$34.43 High Price Target$45.00 Low Price Target$20.00 Potential Upside/Downside+116.8%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$2.31 Trailing P/E Ratio6.87 Forward P/E RatioN/A P/E GrowthN/ANet Income-$264.46 million Net Margins42.01% Pretax Margin43.91% Return on Equity49.34% Return on Assets38.61% Debt Debt-to-Equity RatioN/A Current Ratio8.44 Quick Ratio8.44 Sales & Book Value Annual Sales$83.98 million Price / Sales20.66 Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book3.00Miscellaneous Outstanding Shares109,250,000Free Float101,930,000Market Cap$1.73 billion OptionableOptionable Beta1.80 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NRIX) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is Available to ClaimJames Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
